A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life.
The global Deuterated Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Deuterated Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Deuterated Drugs.
Report Scope
The Deuterated Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Deuterated Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Deuterated Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teva
Suzhou Zelgen Biopharmaceuticals
Concert Pharmaceuticals
Vertex Pharmaceuticals
Hinova Pharma
Otsuka Pharmaceutical (Avanir)
Poxel SA (DeuteRx)
Segment by Type
Austedo
Zepsun
Others
Segment by Application
Huntington'S Disease (HD)
Tardive Dyskinesia (TD)
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Deuterated Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Deuterated Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Austedo
1.2.3 Zepsun
1.2.4 Others
1.3 Market by Application
1.3.1 Global Deuterated Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Huntington'S Disease (HD)
1.3.3 Tardive Dyskinesia (TD)
1.3.4 Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Deuterated Drugs Market Perspective (2019-2030)
2.2 Deuterated Drugs Growth Trends by Region
2.2.1 Global Deuterated Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Deuterated Drugs Historic Market Size by Region (2019-2024)
2.2.3 Deuterated Drugs Forecasted Market Size by Region (2025-2030)
2.3 Deuterated Drugs Market Dynamics
2.3.1 Deuterated Drugs Industry Trends
2.3.2 Deuterated Drugs Market Drivers
2.3.3 Deuterated Drugs Market Challenges
2.3.4 Deuterated Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Deuterated Drugs Players by Revenue
3.1.1 Global Top Deuterated Drugs Players by Revenue (2019-2024)
3.1.2 Global Deuterated Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Deuterated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Deuterated Drugs Revenue
3.4 Global Deuterated Drugs Market Concentration Ratio
3.4.1 Global Deuterated Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Deuterated Drugs Revenue in 2023
3.5 Deuterated Drugs Key Players Head office and Area Served
3.6 Key Players Deuterated Drugs Product Solution and Service
3.7 Date of Enter into Deuterated Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Deuterated Drugs Breakdown Data by Type
4.1 Global Deuterated Drugs Historic Market Size by Type (2019-2024)
4.2 Global Deuterated Drugs Forecasted Market Size by Type (2025-2030)
5 Deuterated Drugs Breakdown Data by Application
5.1 Global Deuterated Drugs Historic Market Size by Application (2019-2024)
5.2 Global Deuterated Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Deuterated Drugs Market Size (2019-2030)
6.2 North America Deuterated Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Deuterated Drugs Market Size by Country (2019-2024)
6.4 North America Deuterated Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Deuterated Drugs Market Size (2019-2030)
7.2 Europe Deuterated Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Deuterated Drugs Market Size by Country (2019-2024)
7.4 Europe Deuterated Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Deuterated Drugs Market Size (2019-2030)
8.2 Asia-Pacific Deuterated Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Deuterated Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Deuterated Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Deuterated Drugs Market Size (2019-2030)
9.2 Latin America Deuterated Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Deuterated Drugs Market Size by Country (2019-2024)
9.4 Latin America Deuterated Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Deuterated Drugs Market Size (2019-2030)
10.2 Middle East & Africa Deuterated Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Deuterated Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Deuterated Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Deuterated Drugs Introduction
11.1.4 Teva Revenue in Deuterated Drugs Business (2019-2024)
11.1.5 Teva Recent Development
11.2 Suzhou Zelgen Biopharmaceuticals
11.2.1 Suzhou Zelgen Biopharmaceuticals Company Detail
11.2.2 Suzhou Zelgen Biopharmaceuticals Business Overview
11.2.3 Suzhou Zelgen Biopharmaceuticals Deuterated Drugs Introduction
11.2.4 Suzhou Zelgen Biopharmaceuticals Revenue in Deuterated Drugs Business (2019-2024)
11.2.5 Suzhou Zelgen Biopharmaceuticals Recent Development
11.3 Concert Pharmaceuticals
11.3.1 Concert Pharmaceuticals Company Detail
11.3.2 Concert Pharmaceuticals Business Overview
11.3.3 Concert Pharmaceuticals Deuterated Drugs Introduction
11.3.4 Concert Pharmaceuticals Revenue in Deuterated Drugs Business (2019-2024)
11.3.5 Concert Pharmaceuticals Recent Development
11.4 Vertex Pharmaceuticals
11.4.1 Vertex Pharmaceuticals Company Detail
11.4.2 Vertex Pharmaceuticals Business Overview
11.4.3 Vertex Pharmaceuticals Deuterated Drugs Introduction
11.4.4 Vertex Pharmaceuticals Revenue in Deuterated Drugs Business (2019-2024)
11.4.5 Vertex Pharmaceuticals Recent Development
11.5 Hinova Pharma
11.5.1 Hinova Pharma Company Detail
11.5.2 Hinova Pharma Business Overview
11.5.3 Hinova Pharma Deuterated Drugs Introduction
11.5.4 Hinova Pharma Revenue in Deuterated Drugs Business (2019-2024)
11.5.5 Hinova Pharma Recent Development
11.6 Otsuka Pharmaceutical (Avanir)
11.6.1 Otsuka Pharmaceutical (Avanir) Company Detail
11.6.2 Otsuka Pharmaceutical (Avanir) Business Overview
11.6.3 Otsuka Pharmaceutical (Avanir) Deuterated Drugs Introduction
11.6.4 Otsuka Pharmaceutical (Avanir) Revenue in Deuterated Drugs Business (2019-2024)
11.6.5 Otsuka Pharmaceutical (Avanir) Recent Development
11.7 Poxel SA (DeuteRx)
11.7.1 Poxel SA (DeuteRx) Company Detail
11.7.2 Poxel SA (DeuteRx) Business Overview
11.7.3 Poxel SA (DeuteRx) Deuterated Drugs Introduction
11.7.4 Poxel SA (DeuteRx) Revenue in Deuterated Drugs Business (2019-2024)
11.7.5 Poxel SA (DeuteRx) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Teva
Suzhou Zelgen Biopharmaceuticals
Concert Pharmaceuticals
Vertex Pharmaceuticals
Hinova Pharma
Otsuka Pharmaceutical (Avanir)
Poxel SA (DeuteRx)
*If Applicable.